Use this URL to cite or link to this record in EThOS:
Title: Translational development of MyD88 as a biomarker for selecting patients with lymphoma responsive to histone deacetylase inhibitors
Author: Sheikh, Semira
Awarding Body: University of Oxford
Current Institution: University of Oxford
Date of Award: 2017
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Histone deacetylase inhibitors (HDIs) are promising new agents for the treatment of haematological malignancy including lymphoma. MyD88 expression and secretion of pro-inflammatory cytokines may contribute to the sensitization of cancer cells to HDI. Moreover, MyD88 may be a direct target for HDAC- and BRD- inhibitors. Therefore, both expression level of MyD88 and MyD88 mutation status could serve as potential biomarkers for HDI sensitivity in patient selection.
Supervisor: La Thangue, Nicholas Sponsor: Cancer Research UK
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available
Keywords: lymphoma biology ; cancer biomarkers